Description: Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Home Page: www.kaziatherapeutics.com
KZIA Technical Analysis
Three International Towers
Sydney,
NSW
2000
Australia
Phone:
1300 787 272
Officers
| Name | Title |
|---|---|
| Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( | CEO, MD & Exec. Director |
| Ms. Karen R. Krumeich | Chief Financial Officer |
| Dr. John E. Friend II, M.D. | Chief Medical Officer |
| Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD | Company Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6881 |
| Price-to-Sales TTM: | 897.7926 |
| IPO Date: | 1999-01-06 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |